• Merck reported significant pipeline progress and new product launches as it prepares for the eventual loss of Keytruda exclusivity.
• The company expanded its portfolio through acquisitions and key collaborations, including work on an advanced Zaire ebolavirus vaccine.
• A CEPI backed partnership seeks to develop a thermostable and more accessible Zaire ebolavirus vaccine, targeting global health and distribution challenges.

For investors watching Merck (NYSE:MRK), the latest updates show a company actively reshaping its portfolio around new products, deals, and partnerships beyond its flagship Keytruda franchise. At a share price of $119.75, the stock carries a 1 year return of 41.1% and a 5 year return of 96.9%, with gains of 10.5% over the past week and 10.0% over the past month.

As Merck moves toward the approaching Keytruda patent cliff, the mix of pipeline advances, acquisitions, and vaccine work, including the Zaire ebolavirus program, frames how its future revenue base could evolve. For investors, the key question is how effectively this broader portfolio can support the business once exclusivity on its legacy blockbuster winds down.

Stay updated on the most important news stories for Merck by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Merck.

Merck’s latest update gives you a mixed but fairly clear picture of a company trading some near term earnings comfort for pipeline depth and new products ahead of Keytruda’s loss of exclusivity. Q4 2025 sales of US$16.4b and full year sales of US$65.0b were slightly higher than a year earlier, while net income and Q4 EPS were lower, reflecting higher spending and deal related costs. The 2026 sales guidance of US$65.5b to US$67.0b sits below where some investors had hoped, which helps explain the cautious share price reaction even with progress in oncology, respiratory, infectious disease and the Zaire ebolavirus program.

How this fits the Merck narrative

This update is very consistent with the recent Merck narratives that focus on building a broader earnings base around Winrevair, newer vaccines and a tripled late phase pipeline rather than relying on Keytruda alone. The continued dividend at US$0.85 per share, selective M&A such as Verona, Cidara and Sidera, and partnerships in oncology and vaccines all line up with the story of a company trying to pre fund its future revenue gap in a similar way to peers like Pfizer and Bristol Myers Squibb.

Risks and rewards investors are weighing

• ⚠️ 2026 guidance below analyst expectations, plus generic pressure on older drugs and Gardasil demand uncertainty, keeps the risk that earnings growth slows while Merck invests heavily.
• ⚠️ Analysts have flagged Merck’s higher debt levels and the possibility of larger transactions as areas where capital allocation and integration risk need close monitoring.
• 🎁 On the positive side, management points to a very large commercial opportunity from new launches and the broader pipeline by the mid 2030s, which is intended to offset the Keytruda patent cliff.
• 🎁 Recent approvals such as the RSV antibody ENFLONSIA and the CEPI backed Zaire ebolavirus work add to Merck’s vaccines and infectious disease portfolio, an area investors often associate with recurring demand and global health funding.

What to watch next

From here, investors are likely to focus on how quickly newer products ramp, the pace of late stage trial readouts, and any further deals in the US$1b to US$15b range, especially given broader sector interest in bolt on transactions. If you want to see how other investors connect these earnings, deals and pipeline updates into a longer term story, take a look at the community narratives for Merck on this dedicated page.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.